IpiNovyx Bio is a New York-based biotech company, developing immunoproteasome inhibitors for the treatment of autoimmune diseases. Their leading compounds are highly selective and reversible immunoproteasome inhibitors, showed promising in vitro and in vivo efficacy, and a good safety profile. The leadership team is highly experienced industry veterans.

‍